

# Calcium folinate (leucovorin calcium)



Essential medicine status

Section: [8. Immunomodulators and antineoplastics](#) > [8.2. Antineoplastics and supportive medicines](#) > [8.2.1. Cytotoxic medicines](#)

		EMLc	ATC codes: <b>V03AF03</b>
Indication	Burkitt lymphoma including Burkitt leukaemia	ICD11 code: <b>2B55.6</b>	
INN	Calcium folinate		
Medicine type	Chemical agent		
List type	Complementary (EML) (EMLc)		
Formulations	Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule ; 7.5 mg per mL in 2 mL ampoule ; 10 mg per mL in 5 mL ampoule Oral > Solid > tablet: 15 mg ; 5 mg ; 25 mg		
EML status history	First added in 1979 ( <a href="#">TRS 641</a> ) Changed in 2015 ( <a href="#">TRS 994</a> ) Changed in 2019 ( <a href="#">TRS 1021</a> ) Changed in 2023 ( <a href="#">TRS 1049</a> )		
Sex	All		
Age	Also recommended for children		
Therapeutic alternatives	The recommendation is for this specific medicine		
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> .		
Tags	<a href="#">Cancer</a>		
Wikipedia	<a href="#">Calcium folinate (leucovorin calcium)</a>		
DrugBank	<a href="#">Calcium folinate (Leucovorin)</a>		

## Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of new strength formulations of calcium folinate (Injection: 7.5 mg/mL in 2 mL ampoule; 10 mg/mL in 5 mL ampoule) to the EML and EMLc.

